Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345499 | 1.00 | NPC1 (0.58) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2350791 | 0.97 | NPC1 (0.61) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2350799 | 0.97 | NPC1 (0.61) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2347782 | 0.89 | NPC1 (0.62) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2347773 | 0.89 | NPC1 (0.62) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2347121 | 0.86 | NPC1 (0.66) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2347111 | 0.86 | NPC1 (0.66) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL2350255 | 0.81 | RAB9A (0.62) | NPC1KMT2ALMNANPSR1ALDH1A1 | |
| SCHEMBL2344552 | 0.81 | NPC1 (0.48) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL4601582 | 0.81 | MEN1 (0.67) | NPC1MEN1KMT2ALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008303-B2 | e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | NPC1 146/4885MEN1 3163/4885KMT2A 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.